Increased expression of Bcl-X(L) has been reported in a variety of different malignancies including AML and multiple myeloma as well as solid cancers like bladder cancer, breast cancer, pancreatic cancer and melanoma [13]. Here, BCL2L1 is linked to plasma cell myeloma.